+34 948 346 255 / info@medibiofarma.com

Investors

The company is owned primarily by the founders together with our financial partners: Sodena, Inveready and Fitalent which entered the company in 2019

 

PUBLIC FUNDS

This company has received a grant co-financed 50% by the European Regional Development Fund through the Operative Program FEDER 2014-2020 of Navarra, for the following projects:

  1. “Discovery of new PPAR-gamma antagonists for the treatment of bladder cancer” (0011-1365-2018-000110)
  2. “Clinical development of MBF-118: An PPAR-g receptor antagonist as new treatment for bladder cancer (Antago-PPAR-ɣ) (0011-1365-2019-000059)”
  3. “Industrial research project based on the design and discovery of new dual antagonists of prostaglandin E2 receptors (EP2/EP4) for the treatment of cancer (PGE2-Cancer) (0011-1365-2019-000061 )”
  4. “Clinical development of MBF-015, a histone deacetylase HDAC1/2 inhibitor as a new treatment for Multiple Sclerosis (HDAC-CLINIC) (0011-1365-2021-000264)”

This company has received a grant co-financed 40% by the European Regional Development Fund through the Operative Program FEDER 2021-2027 of Navarra, for the following projects:

  1. “Industrial research and pharmaceutical development of a potent HDAc-8 inhibitor as a drug for the treatment of fibrosis” (acronym: “HDAC-FIBRO”).(0011-1365-2022-000046)
  2. “Industrial research on novel PPAR-γ receptor inverse agonists for the treatment of Crohn’s disease (PPAR-Crohn’s). ( 0011-1365-2023-000165)”

Medibiofarma has received aid from the Government of Navarre, 40% of which is co-financed by the European Regional Development Fund through the  Operational Programme FEDER 2021-2027  for Navarre , for the implementation of the following strategic R&D project:

“Advanced Immuno-Radiotherapy of Navarra (NAIARA).(Código Expediente: 0011-1411-2025-000013)

Medibiofarma has access to FEDER funds through the support of the Ministerio de Economía y Competitividad under the program “CDTI NEOTEC ” and “Retos” to execute the following Projects:

 

  • MEDIBIOFARMA participa en el Proyecto: “INVESTIGACIÓN Y DESARROLLO DE UNA NUEVA TERAPIA PARA EL TRATAMIENTO DE LA ENFERMEDAD DE HUNTINGTON” (CPP2022-009575), como entidad líder del Consorcio creado junto a:

-INSTITUT DE RECERCA DE L HOSPITAL DE LA SANTA CREU I SANT PAU, y

-UNIVERSIDAD DE BARCELONA.

El objetivo principal del proyecto es avanzar en el desarrollo clínico del compuesto oral MBF-015, inhibidor de histonas deacetilasas 1/2 (HDAC1/2), en el tratamiento de enfermedades neurodegenerativas, específicamente en la enfermedad de Huntington. Además, se realizarán estudios con el MBF-015 y otros inhibidores de HDAC1/2, en modelos in vitro e in vivo de dicha enfermedad.

Está prevista su ejecución entre marzo de 2023 y marzo de 2026. El proyecto ha sido financiado por MCIN/AEI/10.13039/501100011033 y por la Unión Europea-NextGenerationEU/PRTR.

 

  • The Ministry of Science and Innovation, within the call for R + D + i Projects “Challenges-Collaboration” of the State Program for Research, Development and Innovation Oriented to the Challenges of Society, within the framework of the State Plan for Scientific Research and Technique and Innovation 2017-2020, granted aid to the project “Discovery and development of new immuno-oncological treatments” in which Medibiofarma, SL participates , with file number RTC2019-006865-1. This project has been funded by the Ministry of Science and Innovation within the RETOS-COLABORACIÓN Subprogram, Call 2019. The project is co-financed by the European Union through the European Regional Development Fund (ERDF) with the aim of promoting technological development, innovation and quality research

 

  • Medibiofarma has received a grant from the Center for Industrial Technological Development E.P.E (CDTI), aimed at new business projects of innovative companies (NEOTEC Program call 2018), for the following project:

“DISCOVERY AND DEVELOPMENT OF NEW IMMUNO-ONCOLOGICAL THERAPIES” (DESCUBRIMIENTO Y DESARROLLO DE NUEVAS TERAPIAS INMUNO-ONCOLÓGICAS) (EXP – 00115172 / SNEO-20181046)

Medibiofarma ha sido beneficiaria, en el marco del Plan de Recuperación, Transformación y Resiliencia y del Programa Estatal de Catalización de la Innovación y Liderazgo Empresarial del Plan Estatal de Investigación Científica, Técnica y de Innovación 2021-2023, de la subvención del “Programa Misiones de Ciencia e Innovación”:

EXP 00146129 / MIP-20211011

Título: INVESTIGACIÓN Y DESARROLLO DE TRES NUEVAS TERAPIAS DIRIGIDAS AL TRATAMIENTO PERSONALIZADO DEL CÁNCER

In 2021, Medibiofarma was financed through a participatory loan from the National Innovation Company S.A. (ENISA) (Ministerio de Industria, Comercio y Turismo) to partially finance the company’s growth plan.

 

A financial instrument of the Government of Navarra to promote business projects in the region that can contribute to the region’s development. Sodena works to try to ensure all viable projects in the self-governing region of Navarra can receive financing to carry them out.

Inveready is a leading alternative asset manager in Spain – investing in early-stage VC, growth VC, venture debt, strategic equity in listed companies, infrastructure and private equity – providing financing solutions to companies throughout their life-cycle.

Founded in 2008, Inveready counts on 177 active companies, 61 exits and more than €1bn of assets under management.

Some of their portfolio companies have been acquired by multinationals such as Intel, Symantec, IBM, and Facebook, whilst others are listed in public markets such as NASDAQ, the Spanish BME Growth, AIM London, and Euronext Growth. (visit www.inveready.com for more information)

Fitalent (FIT Inversión en Talento SCR de Régimen Simplificado SL) is a venture capital company established in early 2011 and registered in the Special Registry of the National Securities Market Commission (CNMV) which invests in technology-based companies with proven track record.